Nyxoah

Update in progress

NYXH (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryMedical Instruments & Supplies

Nyxoah SA is a medical technology company that develops and commercializes treatments for obstructive sleep apnea (OSA). Its flagship product is the Genio system, a hypoglossal nerve stimulation therapy designed to reduce OSA events. Founded in 2009, Nyxoah is headquartered in Mont-Saint-Guibert, Belgium, and focuses on advancing implantable solutions for sleep-disordered breathing.

Company score

Sentiment: 0.39; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.38; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.08; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.13; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.26; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqGM (NGM)
LocationBelgium
CEOMr. Olivier Taelman
Founded2009
Employees153
Websitewww.nyxoah.com

Identifiers

ISINBE0974358906
FIGIBBG00ZKH4B03
CIK0001857190